Clinical trial · Interventional
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination With Bortezomib to Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT00407303CI-TRIAL-00023183completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mantle-Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bortezomib | Drug | Bortezomib | ALIAS |
| Obatoclax mesylate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 1
- description
- 30mg obatoclax, 1.0mg/m2 bortezomib
- interventionNames
- Drug: Obatoclax mesylate
- Drug: Bortezomib
- type
- EXPERIMENTAL
- label
- 2
- description
- obatoclax 30 mg, bortezomib 1.3 mg/m2
- interventionNames
- Drug: Obatoclax mesylate
- Drug: Bortezomib
- type
- EXPERIMENTAL
- label
- 3
- description
- Obatoclax 45 mg, Bortezomib 1.3 mg/m2
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological confirmation of Mantle Cell Lymphoma (ML) * Must have documented relapse or progression following 1 or 2 prior lines of antineoplastic therapy * Must have normal organ function * Must have the ability to understand and willingness to sign a written informed consent form Exclusion Criteria: * No other agents or therapies administered with the intent to treat malignancy * Patients with prior exposure to obatoclax * Uncontrolled, intercurrent illness * Pregnant women and women who are breast feeding
References
Publications (0)
Data not yet available
No reference posted for this study.